Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zevra Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ZVRA
Nasdaq
2834
https://zevra.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zevra Therapeutics Inc
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
- Apr 15th, 2024 9:01 pm
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
- Apr 10th, 2024 11:30 am
Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Apr 4th, 2024 7:39 pm
Bearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimates
- Apr 3rd, 2024 10:12 am
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 4:46 pm
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price Target
- Mar 31st, 2024 12:43 pm
Q4 2023 Zevra Therapeutics Inc Earnings Call
- Mar 29th, 2024 4:07 pm
Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ...
- Mar 28th, 2024 10:11 pm
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Mar 28th, 2024 8:32 pm
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
- Mar 26th, 2024 8:30 pm
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Mar 25th, 2024 8:30 pm
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
- Mar 21st, 2024 2:00 pm
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
- Mar 18th, 2024 11:30 am
Zevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years ago
- Mar 14th, 2024 6:38 pm
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
- Mar 4th, 2024 12:30 pm
Zevra Therapeutics to Participate at Upcoming Investor Conferences
- Feb 28th, 2024 12:30 pm
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
- Feb 15th, 2024 8:49 am
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 12:30 pm
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
- Feb 1st, 2024 1:19 pm
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
- Jan 23rd, 2024 12:30 pm
Scroll